Tramazoline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tramazoline
Accession Number
DB13064
Type
Small Molecule
Groups
Investigational
Description

Tramazoline is under investigation in clinical trial NCT01601509 (Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
SLE31693IV
CAS number
1082-57-1
Weight
Average: 215.3
Monoisotopic: 215.142247559
Chemical Formula
C13H17N3
InChI Key
QQJLHRRUATVHED-UHFFFAOYSA-N
InChI
InChI=1S/C13H17N3/c1-2-6-11-10(4-1)5-3-7-12(11)16-13-14-8-9-15-13/h3,5,7H,1-2,4,6,8-9H2,(H2,14,15,16)
IUPAC Name
N-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine
SMILES
C1CN=C(NC2=CC=CC3=C2CCCC3)N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tramazoline.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tramazoline.Approved, Illicit, Investigational
AtomoxetineAtomoxetine may increase the hypertensive activities of Tramazoline.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tramazoline.Approved, Illicit
BucindololThe risk or severity of adverse effects can be increased when Bucindolol is combined with Tramazoline.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Caffeine.Approved
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Tramazoline.Approved, Investigational
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Tramazoline.Illicit, Withdrawn
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Tramazoline.Approved, Investigational, Vet Approved
DiethylpropionThe risk or severity of adverse effects can be increased when Tramazoline is combined with Diethylpropion.Approved, Illicit
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tramazoline.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Tramazoline.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Tramazoline.Approved, Illicit
EpanololThe risk or severity of adverse effects can be increased when Tramazoline is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Tramazoline.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Tramazoline.Approved, Vet Approved
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Tramazoline.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Tramazoline.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Tramazoline is combined with Fenozolone.Experimental
GanciclovirThe risk or severity of adverse effects can be increased when Tramazoline is combined with Ganciclovir.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Tramazoline.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Tramazoline.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Tramazoline.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Tramazoline.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Tramazoline.Approved
LinezolidLinezolid may increase the hypertensive activities of Tramazoline.Approved, Investigational
MefenorexThe risk or severity of adverse effects can be increased when Tramazoline is combined with Mefenorex.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tramazoline.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Tramazoline.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tramazoline.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Tramazoline.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Tramazoline.Approved
NabiloneNabilone may increase the tachycardic activities of Tramazoline.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Tramazoline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tramazoline.Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Tramazoline.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tramazoline.Approved, Investigational
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Tramazoline.Approved, Illicit
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tramazoline.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Tramazoline.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Tramazoline.Approved, Vet Approved, Withdrawn
PrenalterolThe risk or severity of adverse effects can be increased when Tramazoline is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Tramazoline.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Pseudoephedrine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Tramazoline.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Tramazoline.Approved, Investigational
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Tramazoline.Experimental
Tedizolid phosphateTedizolid Phosphate may increase the hypertensive activities of Tramazoline.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tramazoline.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Tramazoline.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Tramazoline is combined with Tretoquinol.Experimental
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Tramazoline.Investigational, Nutraceutical
ValaciclovirThe risk or severity of adverse effects can be increased when Tramazoline is combined with Valaciclovir.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Tramazoline.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5524
PubChem Substance
347829192
ChemSpider
5323
BindingDB
50027056
ChEBI
134893
ChEMBL
CHEMBL32573
Wikipedia
Tramazoline
ATC Codes
R01AA09 — Tramazoline

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.408 mg/mLALOGPS
logP2.27ALOGPS
logP2.73ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)9.89ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity66.96 m3·mol-1ChemAxon
Polarizability25.05 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Tetralins
Sub Class
Not Available
Direct Parent
Tetralins
Alternative Parents
Imidazolines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tetralin / 2-imidazoline / Guanidine / Azacycle / Organoheterocyclic compound / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organic nitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 20:35 / Updated on August 02, 2018 06:47